Conteltinib free base · Synonyms: CT-707

Conteltinib (CT-707) is a multi-kinase inhibitor targeting FAK, ALK, and Pyk2.

For research use only. Not for human or veterinary use.

Target FAK

Research area Cancer

Purity >98% Stock Inquire

Data Sheet SDS COA

Conteltinib structure

CAS No.: 1384860-29-0

Download structure (.mol)

Pack sizes & pricing

Size	Price	SKU	Stock
50 mg	USD 880.00	BP-02358-50mg	In stock	Get quote
100 mg	USD 1,350.00	BP-02358-100mg	In stock	Get quote
500 mg	Inquire	BP-02358-500mg	In stock	Inquire
1 g	Inquire	BP-02358-1g	In stock	Inquire

Need another size or custom synthesis? Request a quote.

Description

Conteltinib (CT-707) is a multi-kinase inhibitor targeting FAK, ALK, and Pyk2. Conteltinib exerts significant inhibitory effect on FAK with an IC50 of 1.6 nM.

Biological activity

Conteltinib (CT-707) is a potent second-generation mesenchymal lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) with antitumor activity for studies related to hepatocellular carcinoma (HCC).

Identifiers

SMILES: O=S(C1=C(C=CC=C1)NC2=C(CCN3)C3=NC(NC(C=CC(N4CCC(N5CCN(C)CC5)CC4)=C6)=C6OC)=N2)(NC(C)C)=O
InChIKey: NPJCURIANJMFEO-UHFFFAOYSA-N

Specifications

MW (average): 635.8230
Formula: C₃₂H₄₅N₉O₃S
CAS No.: 1384860-29-0
Physical state: Solid
Color: Light yellow to yellow
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: Powder -20℃ 2 years; In solvent -20℃ 1 month;

Solubility

Soluble in DMSO

In vitro: DMSO 31.25 mg/mL

Documents

References

[1]. Wang DD, et al. CT-707, a Novel FAK Inhibitor, Synergizes with XL184 to Suppress Hepatocellular Carcinoma by Blocking XL184-Induced FAK Activation. Mol Cancer Ther. 2016 Dec;15(12):2916-2925.

Same target

Search FAK

Same research area

Search Cancer